Back to Journals » Therapeutics and Clinical Risk Management » Volume 15

Anticholinergics in asthma: are we utilizing asthma therapies effectively?

Authors Vogelberg C

Received 10 October 2018

Accepted for publication 15 October 2018

Published 14 March 2019 Volume 2019:15 Pages 405—408

DOI https://doi.org/10.2147/TCRM.S190363

Checked for plagiarism Yes

Editor who approved publication: Professor Garry Walsh


Christian Vogelberg

Department of Pediatric Pulmonology and Allergy, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany

Data have shown that asthma is the most prevalent chronic respiratory disease, affecting 358 million people worldwide in 2015.1 While data show that the age-standardized asthma-related death rate decreased by 58.8% from 1990–2015,1 asthma still represents a significant burden in terms of morbidity.2 As such, there is an important role for utilizing add-on therapy options. The focus of this review series is on the use of long-acting anticholinergic add-on therapy to reduce asthma morbidity.


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]